Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 3, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and...
-
Sep 5, 2019- Expands U.S. OTC market and gastrointestinal category leadership positions
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid® from GlaxoSmithKline. Under the terms of the...
-
Aug 22, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples...
-
Aug 21, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc....
-
Aug 8, 2019
GAAP ("reported") net sales were $1.15 billion, reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased by approximately 1% excluding the unfavorable impact...
-
Aug 7, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief...
-
Jul 31, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21...
-
Jul 25, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference...
-
Jul 8, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million. Perrigo...
-
Jul 3, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug...